Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer

doi:10.1177/1756283X16658251

CORC > 兰州大学 > 兰州大学 > 第一临床医学院 > 期刊论文

	Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
	Liu, XJ; Yang, ZX; Latchoumanin, O; Qiao, L; Qiao, L (reprint author), Univ Sydney, Westmead Hosp, Storr Liver Unit, Westmead Inst Med Res, Westmead, NSW 2145, Australia.
刊名	THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
	2016-11
卷号	9 期号:6 页码:853-860
关键词	gastric cancer immune checkpoint molecules programmed death-1 programmed death ligand-1
ISSN号	1756-283X
DOI	10.1177/1756283X16658251
文献子类	Review
英文摘要	Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are the two important checkpoint molecules with great potential in targeted cancer therapy. Several antibodies targeting PD-1 and PD-L1 have been approved for clinical use. In this review, we focus on the recent development of targeting PD-1 and PD-L1 in gastric cancer (GC) therapy.
学科主题	Gastroenterology & Hepatology
出版地	LONDON
资助项目	澳大利亚国立健康与医学研究理事会项目 ; 甘肃省自然科学基金计划
项目编号	Natural Science Foundation of Gansu, China [145RJZA036] ; Cancer Council NSW grant [APP1070076] ; NHMRC grant [APP1047417]
语种	英语
WOS记录号	WOS:000393291500010
资助机构	NHMRC ; GSSTD
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/188653]
专题	第一临床医学院_期刊论文
通讯作者	Qiao, L (reprint author), Univ Sydney, Westmead Hosp, Storr Liver Unit, Westmead Inst Med Res, Westmead, NSW 2145, Australia.
推荐引用方式 GB/T 7714	Liu, XJ,Yang, ZX,Latchoumanin, O,et al. Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer[J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY,2016,9(6):853-860.
APA	Liu, XJ,Yang, ZX,Latchoumanin, O,Qiao, L,&Qiao, L .(2016).Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer.THERAPEUTIC ADVANCES IN GASTROENTEROLOGY,9(6),853-860.
MLA	Liu, XJ,et al."Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer".THERAPEUTIC ADVANCES IN GASTROENTEROLOGY 9.6(2016):853-860.